JP6875372B2 - 縮合環ピリミジン系化合物、中間体、その製造方法、組成物及び応用 - Google Patents
縮合環ピリミジン系化合物、中間体、その製造方法、組成物及び応用 Download PDFInfo
- Publication number
- JP6875372B2 JP6875372B2 JP2018503190A JP2018503190A JP6875372B2 JP 6875372 B2 JP6875372 B2 JP 6875372B2 JP 2018503190 A JP2018503190 A JP 2018503190A JP 2018503190 A JP2018503190 A JP 2018503190A JP 6875372 B2 JP6875372 B2 JP 6875372B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- compound
- alkyl group
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCC(CCCC1)C1C(C)CC(C*C)C(C)C1C(C)CCC(C)C1 Chemical compound CCC(CCCC1)C1C(C)CC(C*C)C(C)C1C(C)CCC(C)C1 0.000 description 15
- UOPCRLBTGQFVNM-UHFFFAOYSA-N Bc1cccc(cn2)c1nc2Cl Chemical compound Bc1cccc(cn2)c1nc2Cl UOPCRLBTGQFVNM-UHFFFAOYSA-N 0.000 description 1
- OEXNVHXUPNHOPP-UHFFFAOYSA-N CC(C)[n]1ncc(N)c1 Chemical compound CC(C)[n]1ncc(N)c1 OEXNVHXUPNHOPP-UHFFFAOYSA-N 0.000 description 1
- VYPUZEPAWIWESV-UHFFFAOYSA-N CC(C)[n]1ncc(Nc(nc23)ncc2[s]c(C)c3-c2ccccc2OC)c1 Chemical compound CC(C)[n]1ncc(Nc(nc23)ncc2[s]c(C)c3-c2ccccc2OC)c1 VYPUZEPAWIWESV-UHFFFAOYSA-N 0.000 description 1
- CBSSFOTWGVIHFX-UHFFFAOYSA-N CC(C)[n]1ncc([N+]([O-])=O)c1 Chemical compound CC(C)[n]1ncc([N+]([O-])=O)c1 CBSSFOTWGVIHFX-UHFFFAOYSA-N 0.000 description 1
- UYUZAINDUKTQRC-UHFFFAOYSA-N CC([F]C1C=NC(Nc2c[n](C)nc2)=NC11)=C1c(ccc(S(C)(=O)=O)c1)c1OC Chemical compound CC([F]C1C=NC(Nc2c[n](C)nc2)=NC11)=C1c(ccc(S(C)(=O)=O)c1)c1OC UYUZAINDUKTQRC-UHFFFAOYSA-N 0.000 description 1
- WDKUXUZYKCXAHC-UHFFFAOYSA-N CC1(C)COCC1 Chemical compound CC1(C)COCC1 WDKUXUZYKCXAHC-UHFFFAOYSA-N 0.000 description 1
- XORHNJQEWQGXCN-UHFFFAOYSA-N [O-][N+](c1c[nH]nc1)=O Chemical compound [O-][N+](c1c[nH]nc1)=O XORHNJQEWQGXCN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510430641.5 | 2015-07-21 | ||
| CN201510430641 | 2015-07-21 | ||
| PCT/CN2016/090798 WO2017012559A1 (zh) | 2015-07-21 | 2016-07-21 | 稠环嘧啶类化合物、中间体、其制备方法、组合物和应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520202A JP2018520202A (ja) | 2018-07-26 |
| JP2018520202A5 JP2018520202A5 (enExample) | 2018-09-06 |
| JP6875372B2 true JP6875372B2 (ja) | 2021-05-26 |
Family
ID=57833793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503190A Active JP6875372B2 (ja) | 2015-07-21 | 2016-07-21 | 縮合環ピリミジン系化合物、中間体、その製造方法、組成物及び応用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10494378B2 (enExample) |
| EP (1) | EP3354653B1 (enExample) |
| JP (1) | JP6875372B2 (enExample) |
| KR (1) | KR102591886B1 (enExample) |
| CN (1) | CN106366093B (enExample) |
| AU (1) | AU2016295594B2 (enExample) |
| CA (1) | CA2993096C (enExample) |
| MX (1) | MX379383B (enExample) |
| RU (1) | RU2732576C2 (enExample) |
| WO (1) | WO2017012559A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109305944B (zh) * | 2017-07-28 | 2022-09-02 | 深圳睿熙生物科技有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
| CN110551142B (zh) * | 2018-05-31 | 2023-05-12 | 上海再极医药科技有限公司 | 一种稠环嘧啶类化合物的盐、晶型及其制备方法和应用 |
| AU2019309693B2 (en) * | 2018-07-23 | 2023-03-16 | Celgene Quanticel Research, Inc. | Process for the preparation of bromodomain inhibitor |
| CN111978331B (zh) * | 2019-05-21 | 2023-06-20 | 上海再极医药科技有限公司 | 一种flt3和fgfr激酶抑制剂的制备方法 |
| WO2021148010A1 (zh) * | 2020-01-22 | 2021-07-29 | 南京明德新药研发有限公司 | 吡唑并杂芳环类化合物及其应用 |
| WO2021175155A1 (zh) * | 2020-03-06 | 2021-09-10 | 广州再极医药科技有限公司 | 噻吩并嘧啶类衍生物及其制备方法 |
| WO2021180032A1 (en) * | 2020-03-13 | 2021-09-16 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Novel Therapeutic Methods |
| CN116621843B (zh) * | 2022-06-13 | 2024-05-24 | 四川大学华西医院 | 一种dna甲基转移酶1抑制剂及其制备方法和用途 |
| WO2024020380A1 (en) * | 2022-07-18 | 2024-01-25 | Iambic Therapeutics, Inc. | Quinazoline compounds and methods of use |
| WO2024041633A1 (zh) * | 2022-08-25 | 2024-02-29 | 广州再极医药科技有限公司 | 一种稠环嘧啶类化合物的用途 |
| CN116836171B (zh) * | 2023-06-30 | 2024-06-04 | 凌科药业(杭州)有限公司 | 一种磺酰胺类化合物及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5110347A (en) * | 1990-11-26 | 1992-05-05 | E. I Du Pont De Nemours And Company | Substituted fused heterocyclic herbicides |
| US5633218A (en) * | 1995-05-24 | 1997-05-27 | E. I. Du Pont De Nemours And Company | Herbicidal benzodioxoles and benzodioxanes |
| ES2270867T3 (es) * | 1999-09-23 | 2007-04-16 | Astrazeneca Ab | Compuestos de quinazolina terapeuticos. |
| WO2007053452A1 (en) * | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| KR101533461B1 (ko) * | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체 |
| SI2215094T1 (sl) * | 2007-11-15 | 2016-05-31 | Ym Biosciences Australia Pty Ltd | N vsebujoče heterociklične spojine |
| SG172857A1 (en) * | 2009-02-09 | 2011-08-29 | Supergen Inc | Pyrrolopyrimidinyl axl kinase inhibitors |
| TWI468402B (zh) * | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| KR101147550B1 (ko) * | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| WO2011079231A1 (en) * | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| US20130317045A1 (en) | 2010-09-01 | 2013-11-28 | Ambit Biosciences Corporation | Thienopyridine and thienopyrimidine compounds and methods of use thereof |
| TW201309655A (zh) * | 2011-01-28 | 2013-03-01 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| CA2881279C (en) * | 2012-08-07 | 2020-07-07 | Merck Patent Gmbh | Pyridopyrimidine derivatives as protein kinase inhibitors |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| ES3069593T3 (en) * | 2013-08-23 | 2026-06-09 | Neupharma Inc | Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer |
| TWI659021B (zh) * | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| EP3270694A4 (en) | 2015-02-17 | 2018-09-05 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN108299425B (zh) * | 2015-03-24 | 2020-09-18 | 上海璎黎药业有限公司 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
| CN106220644B (zh) * | 2015-04-24 | 2020-07-31 | 广州再极医药科技有限公司 | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 |
-
2016
- 2016-07-21 US US15/746,254 patent/US10494378B2/en active Active
- 2016-07-21 CN CN201610579459.0A patent/CN106366093B/zh active Active
- 2016-07-21 AU AU2016295594A patent/AU2016295594B2/en active Active
- 2016-07-21 EP EP16827250.8A patent/EP3354653B1/en active Active
- 2016-07-21 JP JP2018503190A patent/JP6875372B2/ja active Active
- 2016-07-21 CA CA2993096A patent/CA2993096C/en active Active
- 2016-07-21 MX MX2018000945A patent/MX379383B/es unknown
- 2016-07-21 WO PCT/CN2016/090798 patent/WO2017012559A1/zh not_active Ceased
- 2016-07-21 KR KR1020187004890A patent/KR102591886B1/ko active Active
- 2016-07-21 RU RU2018103332A patent/RU2732576C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016295594A1 (en) | 2018-03-15 |
| KR20180028521A (ko) | 2018-03-16 |
| BR112018001209A2 (pt) | 2018-09-18 |
| CA2993096C (en) | 2022-04-12 |
| RU2018103332A3 (enExample) | 2019-12-09 |
| US20180208604A1 (en) | 2018-07-26 |
| EP3354653B1 (en) | 2019-09-04 |
| NZ739940A (en) | 2023-09-29 |
| EP3354653A4 (en) | 2018-08-29 |
| CA2993096A1 (en) | 2017-01-26 |
| MX2018000945A (es) | 2018-11-09 |
| MX379383B (es) | 2025-03-10 |
| AU2016295594B2 (en) | 2020-04-16 |
| RU2732576C2 (ru) | 2020-09-21 |
| WO2017012559A1 (zh) | 2017-01-26 |
| KR102591886B1 (ko) | 2023-10-20 |
| RU2018103332A (ru) | 2019-08-21 |
| US10494378B2 (en) | 2019-12-03 |
| EP3354653A1 (en) | 2018-08-01 |
| JP2018520202A (ja) | 2018-07-26 |
| CN106366093B (zh) | 2020-08-18 |
| CN106366093A (zh) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102591886B1 (ko) | 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용 | |
| JP6966423B2 (ja) | 縮合環ピリミジンアミノ誘導体、その製造方法、中間体、薬学的組成物及び応用 | |
| JP4942486B2 (ja) | 受容体チロシンキナーゼの阻害剤としてのピラゾール誘導体 | |
| JP6741699B2 (ja) | 新規な二環式誘導体、それらを調製するためのプロセス及びそれらを含有する医薬組成物 | |
| JP2008540622A (ja) | 化合物 | |
| JP2021525783A (ja) | Ｅｒｋ阻害剤及びその使用 | |
| JP7071389B2 (ja) | アミノピリミジン縮合５員複素環化合物、その中間体、製造方法、薬物組成物および使用 | |
| CA2990088A1 (en) | Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| WO2006049339A1 (ja) | 新規縮環イミダゾール誘導体 | |
| JP6283688B2 (ja) | カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン | |
| US20100298297A1 (en) | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | |
| AU2024245104A1 (en) | Compound acting as wrn helicase inhibitor | |
| CN110248946B (zh) | Menin-MLL相互作用的氮杂环庚烷抑制剂 | |
| JP7335972B2 (ja) | ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途 | |
| HK1234036A1 (en) | Fused pyrimidine compound, intermediate, preparation method therefor, composition and use thereof | |
| JP4655276B2 (ja) | ピラゾロピリミジン化合物のメタンスルホン酸塩、その結晶およびその製造方法 | |
| KR20230038740A (ko) | Cdk9 억제제 및 이의 용도 | |
| BR112018001209B1 (pt) | Composto de pirimidina de anel fundido, intermediário, e método de preparação, composição e uso do mesmo | |
| HK1234036B (en) | Fused pyrimidine compound, intermediate, preparation method therefor, composition and use thereof | |
| NZ739940B2 (en) | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof | |
| CN119899183A (zh) | Pkmyt1抑制剂及其应用 | |
| HK1139670A (en) | New n,n'-2,4-dianilinopyrimidines derivatives, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors | |
| HK1139136A (en) | 2-anilino-4-heteroaryl pyrimidine derivatives, and preparation thereof as medicaments, pharmaceutical compositions, and in particular ikk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180320 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180619 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190521 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200519 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200819 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210305 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210323 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210422 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6875372 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE Ref document number: 6875372 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |